Edge Rewrite
// HTMLRewriter · presentation

This page was redesigned at the edge.

Cloudflare fetched the original article and streamed it through HTMLRewriter to apply an entirely new visual system without rebuilding the source page.

// request.cf · coarse context

A page that knows where it met you.

Only coarse request metadata is shown. This demo does not display or persist visitor IP addresses.

Country
US
Cloudflare location
CMH
Connection
HTTP/2
Language
Not provided

Ray ID: a21e4afecfe40555

Jump to content

Timoprazole

From Wikipedia, the free encyclopedia
Timoprazole
Identifiers
  • 2-[(2-Pyridylmethyl)sulfinyl]-1H-benzimidazole
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC13H11N3OS
Molar mass257.31 g·mol−1
3D model (JSmol)
  • n1ccccc1CS(=O)c2[nH]c3ccccc3n2
  • InChI=1S/C13H11N3OS/c17-18(9-10-5-3-4-8-14-10)13-15-11-6-1-2-7-12(11)16-13/h1-8H,9H2,(H,15,16) checkY
  • Key:HBDKFZNDMVLSHM-UHFFFAOYSA-N checkY
 X markNcheckY (what is this?)  (verify)

Timoprazole is in a class of medications called proton pump inhibitors (PPI) that inhibit gastric acid secretion. While it has never come to market, it was studied early on and is considered to be the "backbone" of the PPI class that succeeded it.[1][2] This medication has high anti-secretory activity, which flared interest along with its simple structure.[3]

References

[edit]
  1. Snaeder W (1996). Drug prototypes and their exploitation. Wiley. pp. 414–5.
  2. Hemenway JN (2007). "Case Study: Omeprazole (Prilosec)". Prodrugs. Biotechnology: Pharmaceutical Aspects. pp. 1313–21. doi:10.1007/978-0-387-49785-3_49. ISBN 978-0-387-49782-2.
  3. Senn-Bilfinger J, Sturm E (2006). "The Development of a New Proton-Pump Inhibitor: The Case History of Pantoprazole". Analogue-based Drug Discovery. pp. 115–36. doi:10.1002/3527608001.ch6. ISBN 978-3-527-60800-3.